Diaceutics PLC (LON:DXRX - Get Free Report) insider Graham Paterson purchased 11,643 shares of the firm's stock in a transaction dated Thursday, January 30th. The stock was acquired at an average cost of GBX 138 ($1.72) per share, with a total value of £16,067.34 ($19,989.23).
Diaceutics Stock Up 0.3 %
Shares of DXRX traded up GBX 0.40 ($0.00) during mid-day trading on Tuesday, reaching GBX 134.40 ($1.67). The company's stock had a trading volume of 35,005 shares, compared to its average volume of 147,276. The company has a market cap of £113.53 million, a price-to-earnings ratio of -4,480.00 and a beta of 0.58. The business has a fifty day moving average of GBX 130.62 and a 200 day moving average of GBX 128.62. The company has a quick ratio of 9.92, a current ratio of 4.85 and a debt-to-equity ratio of 2.93. Diaceutics PLC has a 1 year low of GBX 92.24 ($1.15) and a 1 year high of GBX 151 ($1.88).
Wall Street Analyst Weigh In
Several brokerages have weighed in on DXRX. Canaccord Genuity Group reaffirmed a "buy" rating and issued a GBX 160 ($1.99) target price on shares of Diaceutics in a research report on Tuesday, December 17th. Canaccord Genuity Group reiterated a "buy" rating and issued a GBX 160 ($1.99) price objective on shares of Diaceutics in a research report on Tuesday, December 17th.
Read Our Latest Analysis on Diaceutics
Diaceutics Company Profile
(
Get Free Report)
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.
Recommended Stories
Before you consider Diaceutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Diaceutics wasn't on the list.
While Diaceutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
